SEC Form 4 · accession 0000899243-16-013153
IDEXX LABORATORIES INC /DE · IDXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas Craig
Director
Period of report
Feb 9, 2016
Accepted (ET)
Feb 11, 2016 · 7:23 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874716
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 9, 2016 | M | 2,054 | $17.185 | A | 24,352 | D | |
| Common StockF1 | Feb 9, 2016 | S | 2,054 | $69.5243 | D | 22,298 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right-to-buy)F3,F2 | $17.185 | Feb 9, 2016 | M | 2,054 | D | — | Feb 13, 2016 | Common Stock | 2,054 | 0 | D |
Explanation of responses
- F1The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $69.2738 to $69.8301 inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
- F2Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,527 shares on February 14, 2010, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- F3Not applicable.